Most agencies would have said yes, taken the retainer, and let you find out the hard way. I would rather lose the deal than build you a campaign that gets your accounts permanently banned. So here is what I actually found, including the part that has nothing to do with ads.
Not because of the compounds, and not because nobody advertises in this space. Because of one structural detail in how your business is set up. That detail is the whole story, and it is worth understanding before anyone spends a dollar.
Google prohibits promotion of unapproved pharmaceuticals and supplements "regardless of any claims of legality." Research peptides sit squarely in that category. The escalation path for healthcare violations is suspension on detection, and reinstatement only in what Google calls compelling circumstances.
TikTok prohibits products containing substances classified as performance-enhancing by WADA and USADA, which explicitly names peptide hormones and SARMs. Its weight-management policy independently blocks a second chunk of the catalog, and health claims are restricted on top of that.
You have 50 published articles, including twelve head-to-head competitor comparisons and eight "alternatives" pages. That is the highest commercial intent traffic in this entire category, and it is the one acquisition channel no platform can switch off.
An agency that runs these campaigns anyway is not being aggressive on your behalf. They are spending your budget to get your domain and your business manager burned, and you keep the damage after they move on.
You do. They are real, they are paid, and they are running legally. The reason you cannot run them is not the molecule. It is the business model behind it.
Prescriber in the loop. Telehealth providers, pharmacies, physician-owned medspas, and longevity clinics can hold LegitScript certification, which TikTok, Google and Meta all recognize. Those are the paid peptide ads in your feed.
No ad account at all. A creator films a before and after and drops a discount code. Reviewed reactively across billions of posts, not pre-approved. A large share of what looks like advertising is this.
Research use only, no prescriber. Vials labelled not for human consumption, sold direct. That model matches none of the certifiable categories, so there is no version of the ad account that survives review.
This is the part worth sitting with, because it is a strategic question and not an advertising one. The door is not welded shut. It opens on business structure, not on better creative or a smarter agency. If you ever put a licensed prescriber in the loop, the certified lane and everything in it becomes available to you. That is a real decision with real cost, and it is yours to make, not mine. What I am not willing to do is take your budget to run the uncertified version and hand you back a dead ad account and a burned domain.
Here is a live Sponsored products carousel, captured 26 July 2026. Four advertisers. Look at what they have in common.
Two of the four put Rx in the brand name. Every one runs a prescriber-led monthly subscription. And sermorelin is a growth hormone peptide, the same family you stock. AgelessRx advertises it at $99 a month. You cannot advertise it at any price. Identical molecule, different structure.
Now scroll that carousel as long as you like and count the research-use-only vials in it. There are none, and there is a reason for that.
The FDA's Pharmacy Compounding Advisory Committee met on 23 and 24 July 2026 to review seven peptides for compounding eligibility: BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon and Emideltide. At least five of those are in your catalog. Ahead of the meeting the FDA's own scientists recommended against changing the status of any of them, and reporting on the outcome is still moving.
I am not going to tell you how that lands, because nobody credible knows yet. I am telling you it happened three days ago, that it touches most of your top sellers, and that it is the single thing most likely to reshape what this business is allowed to be over the next year. Any plan that does not account for it is not a plan.
Someone did real work here. The content library is genuinely well built, and it is aimed exactly where it should be: people comparing you against a competitor by name, which is the last search someone makes before they buy. Then every one of those readers hits a wall.
articles live, aimed at buyers
product pages Google is allowed to see
User-Agent: * Allow: / Disallow: /shop # the catalog Disallow: /product/ # every single product page Disallow: /bundles Disallow: /about # the page that sells your credibility Disallow: /contact ...
Read that next to your own manifesto. The site says the industry has a transparency problem, and that researchers deserve a supply chain they can verify. Then it hides the About page from search engines and asks for an email address before showing a price. The positioning is right. The plumbing is arguing with it.
You do not have a traffic problem that ads would fix. You have 50 articles pointed at a storefront that search engines cannot enter and buyers have to knock on.
Nothing here needs a platform's permission, which is the entire point in a category that can lose paid access overnight.
Decide deliberately what search is allowed to see, then rebuild the path from article to purchase. Public, indexable compound pages with the COA visible, pricing logic that does not demand a signup before a stranger can judge whether you are expensive, and the About page doing its job. This is the change that makes every article you already paid for start earning.
Weeks 1 to 3Right now there is no way to answer which of the 50 articles produced revenue. Tracking from article to account creation to first order, per post, so the content budget goes to the twelve pages that actually convert instead of being spread evenly across fifty. Most of the lift in month two comes from cutting, not adding.
Weeks 2 to 4Expand the comparison and alternatives set, which is the highest-intent traffic in the category and the format you already rank for. Then the two owned channels no policy can touch: email and SMS to a list of buyers who reorder on a predictable cycle, and the affiliate program you have already built but are not yet running as an actual channel.
Month 2 onwardBy this point the storefront converts and you know which content earns. If you want paid reach then, the honest conversation is not about creative, it is about whether you ever intend to put a licensed prescriber in the loop, because that is the switch that opens the certified lane. If the answer is no, we scale the channels that do not need anyone's approval and I will tell you plainly that there is no paid play worth your money. That answer is worth more than a campaign I already know gets shut off.
When the first three are doneIf any of this is wrong, tell me and I will correct it. If it is right, the fastest thing we can do is get on a call and walk through what opening the storefront actually involves, because that one change is worth more than any ad budget you were about to spend.